Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 Debt-to-Equity is 1.29 as of Mar. 2026, which is 180% above its 10-year median of 0.46. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 89.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Boule Diagnostics AB's Debt-to-Equity or its related term are showing as below:
CHIX:BOULs'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.46 Max: 1.34
Current: 1.29
During the past 13 years, the highest Debt-to-Equity Ratio of Boule Diagnostics AB was 1.34. The lowest was 0.09. And the median was 0.46.
CHIX:BOULs's Debt-to-Equity is ranked worse than 89.24% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs CHIX:BOULs: 1.29
Boule Diagnostics AB (CHIX:BOULs) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Boule Diagnostics AB Debt-to-Equity Related Terms
Boule Diagnostics AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Debt-to-Equity of 1.29 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Boule Diagnostics AB and its competitors. This is 180% above median its historical median of 0.46. Over the past decade, Boule Diagnostics AB's Debt-to-Equity has ranged from 0.09 to 1.34. According to the industry distribution chart, Boule Diagnostics AB ranks #630 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 89.2%.
Is Boule Diagnostics AB's Debt-to-Equity too high?
Boule Diagnostics AB's current Debt-to-Equity of 1.29 is 180% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 1.34. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Boule Diagnostics AB's value of 1.29 is 473.3% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #630 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #630 out of 706 companies for Debt-to-Equity. This places Boule Diagnostics AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Boule Diagnostics AB's value of 1.29 is 473.3% above this benchmark. Historically, Boule Diagnostics AB's own Debt-to-Equity has ranged from 0.09 to 1.34 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.23, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Debt-to-Equity of 1.29 is 473.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Debt-to-Equity is 1.29, which is 180% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Debt-to-Equity of 1.29. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Debt-to-Equity is 1.29, which is 180% above median its 10-year median of 0.46 and 473.3% above the Medical Devices & Instruments industry median of 0.23. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Debt-to-Equity is 1.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.
Key valuation signals for CHIX:BOULS:
Debt-to-Equity: 1.29 (180% above median its 10-year median of 0.46)
GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
Industry Position: 473.3% above the Medical Devices & Instruments median (#630 of 706)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
